182 related articles for article (PubMed ID: 28786276)
21. Animal models of rheumatoid arthritis: How informative are they?
McNamee K; Williams R; Seed M
Eur J Pharmacol; 2015 Jul; 759():278-86. PubMed ID: 25824900
[TBL] [Abstract][Full Text] [Related]
22. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
[TBL] [Abstract][Full Text] [Related]
23. [Rheumatoid Arthritis].
Lehmann J; Kyburz D
Ther Umsch; 2023 Feb; 80(1):27-33. PubMed ID: 36659846
[TBL] [Abstract][Full Text] [Related]
24. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
[TBL] [Abstract][Full Text] [Related]
25. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis.
Cuchacovich M; Catalan D; Wainstein E; Gatica H; Soto L; Aravena O; Pesce B; Sabugo F; Aguillón JC
Clin Exp Rheumatol; 2008; 26(6):1067-73. PubMed ID: 19210871
[TBL] [Abstract][Full Text] [Related]
26. New biomarkers in rheumatoid arthritis.
Willemze A; Toes RE; Huizinga TW; Trouw LA
Neth J Med; 2012 Nov; 70(9):392-9. PubMed ID: 23123533
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Rheumatoid Arthritis: Progress Toward Prevention.
Mankia K; Emery P
Arthritis Rheumatol; 2016 Apr; 68(4):779-88. PubMed ID: 26814677
[No Abstract] [Full Text] [Related]
28. [Proposal for biologic drugs therapy in rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
[TBL] [Abstract][Full Text] [Related]
29. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
[TBL] [Abstract][Full Text] [Related]
30. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease.
Machold KP; Stamm TA; Nell VP; Pflugbeil S; Aletaha D; Steiner G; Uffmann M; Smolen JS
Rheumatology (Oxford); 2007 Feb; 46(2):342-9. PubMed ID: 16899498
[TBL] [Abstract][Full Text] [Related]
31. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression.
Rönnelid J; Wick MC; Lampa J; Lindblad S; Nordmark B; Klareskog L; van Vollenhoven RF
Ann Rheum Dis; 2005 Dec; 64(12):1744-9. PubMed ID: 15843452
[TBL] [Abstract][Full Text] [Related]
33. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis.
Böhler C; Radner H; Smolen JS; Aletaha D
Ann Rheum Dis; 2013 Feb; 72(2):241-4. PubMed ID: 23087181
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategies for rheumatoid arthritis.
O'Dell JR
N Engl J Med; 2004 Jun; 350(25):2591-602. PubMed ID: 15201416
[No Abstract] [Full Text] [Related]
35. The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study.
Klaasen R; Cantaert T; Wijbrandts CA; Teitsma C; Gerlag DM; Out TA; de Nooijer MJ; Baeten D; Tak PP
Rheumatology (Oxford); 2011 Aug; 50(8):1487-93. PubMed ID: 21454308
[TBL] [Abstract][Full Text] [Related]
36. Is there a link between carbamylation and citrullination in periodontal disease and rheumatoid arthritis?
Bright R; Proudman SM; Rosenstein ED; Bartold PM
Med Hypotheses; 2015 Jun; 84(6):570-6. PubMed ID: 25801344
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous development of acute phase response and autoantibodies in preclinical rheumatoid arthritis.
Nielen MM; van Schaardenburg D; Reesink HW; Twisk JW; van de Stadt RJ; van der Horst-Bruinsma IE; de Koning MH; Habibuw MR; Dijkmans BA
Ann Rheum Dis; 2006 Apr; 65(4):535-7. PubMed ID: 16079166
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
40. Seropositivity of Rheumatoid Arthritis Specific Tests in a Patient With Nephrotic Syndrome: Successful Treatment With Rituximab.
Mirzaei A; Ataeipoor Y; Asgari M; Zabihiyeganeh M
Iran J Kidney Dis; 2017 Nov; 11(6):467-468. PubMed ID: 29190608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
